TY - JOUR T1 - The effect of previous SARS-CoV-2 infection and COVID-19 vaccination on SARS-CoV-2 Omicron infection and relation with serological response – a prospective cohort study JF - medRxiv DO - 10.1101/2023.01.09.23284334 SP - 2023.01.09.23284334 AU - Brechje de Gier AU - Anne J. Huiberts AU - Christina E. Hoeve AU - Gerco den Hartog AU - Henri van Werkhoven AU - Rob van Binnendijk AU - Susan J.M. Hahné AU - Hester E. de Melker AU - Susan van den Hof AU - Mirjam J. Knol Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/09/2023.01.09.23284334.abstract N2 - Objectives To estimate the protective effect of previous infections and vaccinations on SARS-CoV-2 Omicron infection.Design Prospective cohort studySetting Community-based cohort, the NetherlandsParticipants 43,257 Community-dwelling adults aged 18-85 years contributed 8,291,966 person-days between 10 January 2022 and 1 September 2022.Main outcome measures SARS-CoV-2 infection, defined as either a reported positive (self-administered) antigen or PCR test, or seroconversion or 4-fold increase in Nucleoprotein-antibodies, based on 6-monthly serum samples. Cox proportional hazard models were used with SARS-CoV-2 infection and any COVID-19 vaccination as time-varying exposures, calendar time as underlying time scale and adjustment for age, sex, medical risk and educational level.Results In participants with 2, 3 or 4 prior immunizing events (vaccination or previous infection), we found a relative reduction of 71-85% in Omicron infection in weeks 4-10 post-last event with hybrid immunity compared to vaccine-induced immunity. Differences in risk of infection were partly explained by differences in anti-Spike RBD (S) antibody concentration, which showed a similar pattern but with smaller differences between vaccine-induced and hybrid immunity. Compared to the lowest quartile, participants in subsequent quartiles of S-antibody concentrations had 19%, 35% and 71% reduced risk of infection, respectively. Among participants with hybrid immunity, with one previous pre-Omicron infection, there was no relevant difference in risk of Omicron infection by sequence of vaccination(s) and infection. Regardless of the type of previous immunizing events, additional events increased the protection against infection, but not above the level of the first weeks after the previous event.Conclusions Our results showed that hybrid immunity is more protective against infection with SARS-CoV-2 Omicron than vaccine-induced immunity, up to at least 30 weeks after the last immunizing event. Among those with hybrid immunity, the sequence and number of immunizing events was not found to be of importance, and its protective effect was partly explained by circulating S-antibodies. In our population with a high level of immunity, additional immunizing events reduced risk of infection with Omicron variants only temporarily.Trial registration Dutch Trial Register (NTR), registration number NL9279 (available via ICTRP Search Portal (who.int))What is already known on this topic Studies have found that a previous infection combined with vaccination (hybrid immunity) lowers the risk of SARS-CoV-2 Omicron infection compared to vaccination alone. These studies are mainly test-negative case-control studies, and may be influenced by the increasing use of self-administered antigen testing, and by untested infections. The importance of the sequence and number of immunizing events in hybrid immunity against Omicron infection, and its association with circulating antibody concentrations, is largely unknown.What this study addsHybrid immunity confers better protection against Omicron infection compared to vaccine-induced immunity, up to at least 30 weeks post-immunizing event, regardless of the sequence or number of immunizing events.The patterns in protection of hybrid immunity against Omicron infection are partly explained by patterns in S-antibody concentration, which was associated with risk of infection in a dose-reponse manner.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279 https://www.researchgate.net/publication/360721847_Design_and_baseline_description_of_an_observational_population-based_cohort_study_on_COVID-19_vaccine_effectiveness_in_the_Netherlands_-_The_VAccine_Study_COvid-19_VASCO Funding StatementThis study was funded by the Dutch Ministry of Health, Welfare and SportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors. ER -